Cline Scientific’s bankruptcy application granted

Cline Scientific AB (publ) ("Cline" or the "Company") communicated earlier today that the company's board decided to submit an application to the Gothenburg district court to declare the company bankrupt. The bankruptcy application has now been granted.  Johan Sölveland, CEO of Ackordscentralen Väst AB, Gothenburg, has been appointed bankruptcy trustee.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.

 This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 11:34 am CEST on 12 August 2024.

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
 

Cline Scientific AB (publ)                                                
Pepparedsleden 1
AstraZeneca BioVentureHub                                               Email: info@clinescientific.com
431 53  MÖLNDAL                                                             Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.